Gabapentin Capsule
Product Images NDC 72789-055

9 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72789-055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

1 (Image 1)
A mathematical formula calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and sex, incorporating an adjustment factor of 0.85 for female patients. This text panel provides guidance on pharmacokinetic adjustments relevant to drug dosing considerations.*
FDA Label Image

1 (Image 3)

1 (Image 3)
Gabapentin 300 mg oral capsules from PD-Rx Pharmaceuticals, Inc. The label displays the product name Gabapentin with the strength 300 mg and the dosage form as capsules. The packaging features a clear blister pack containing white and orange capsules.*
FDA Label Image

1 (Image 5)

1 (Image 5)
Chemical structure diagram showing the molecular structure of gabapentin with a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*
FDA Label Image

1 (Image 6)

1 (Image 6)
A line graph depicting mean pain scores over an 8-week period, comparing a placebo group with a Gabapentin group receiving 3600 mg/day. The x-axis shows weeks from baseline to 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in pain scores for the Gabapentin group compared to placebo.*
FDA Label Image

2 (Image 7)

2 (Image 7)
A line graph showing mean pain score over seven weeks comparing three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period; the y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show decreasing pain scores over time compared to placebo.*
FDA Label Image

3 (Image 8)

3 (Image 8)
A bar chart comparing percent values for placebo (PBO) versus Gabapentin (GBP) at different dosages across two studies. Study 1 shows PBO at 12% and GBP 3600 mg at 29%, while Study 2 shows PBO at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Statistical significance levels (p < 0.01 and p < 0.001) are indicated above GBP bars.*
FDA Label Image

4 (Image 9)

4 (Image 9)
A scatter plot showing differences (%) on the y-axis versus daily dose (mg) on the x-axis for Gabapentin 300 mg capsules. Data points are grouped by three studies labeled a, b, and c, with daily doses ranging from 600 mg to 1800 mg and differences between approximately 7% and 18%.*
FDA Label Image

1 (Image 11)

1 (Image 11)
Gabapentin 300 mg capsule packaging label from PD-Rx Pharmaceuticals, Inc. The label displays the product name Gabapentin, the strength of 300 mg, dosage form as capsules for oral use, with the NDC number 72789-055. The design is simple with white background and text in blue and red.*
FDA Label Image

72789055 Label (72789055)

72789055 Label (72789055)
Gabapentin USP 300 mg capsules label from PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label shows a package containing 180 capsules with NDC 72789-055-93. It includes warnings about drowsiness, avoiding alcohol, and not taking antacids simultaneously. The label also contains reorder number 111087, lot number F20C11, and expiration date 06/2022, with instructions to see the package insert for dosage and storage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.